Korean J Pediatr Hematol Oncol.  2004 Oct;11(2):265-270.

A Case of Ganciclovir-resistant CMV Antigenemia by UL97 Phosphotransferase Mutant Strain after Cord Blood Transplantation

Affiliations
  • 1Department of Pediatrics, The Catholic University of Korea, College of Medicine, Seoul, Korea. cngped@catholic.ac.kr
  • 2Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Abstract

Despite the availability of effective antiviral drugs, human cytomegalovirus (CMV) infection is still a serious life-threatening complication in recipients of allogeneic hematopoietic stem cell transplantation. Ganciclovir (GCV) preemptive therapy is currently the usual treatment for CMV disease and antigenemia. However, prolonged GCV therapy results in the emergence of drug-resistant virus. Most GCV-resistant clinical CMV isolates contain a mutation in the UL97 phosphotransferase gene. We report a case that GCV-resistant CMV antigenemia by UL97 phosphotransferase mutant strain at codon 460 and 605 which was improved by reduction of immunosuppressants for posttransplant lymphoproliferative disease after unrelated cord blood transplantation.

Keyword

Cytomegalovirus; Resistance; Antivirals; UL97

MeSH Terms

Antiviral Agents
Codon
Cytomegalovirus
Fetal Blood*
Ganciclovir
Hematopoietic Stem Cell Transplantation
Humans
Immunosuppressive Agents
Antiviral Agents
Codon
Ganciclovir
Immunosuppressive Agents
Full Text Links
  • KJPHO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error